Seminars in Dialysis最新文献_第2页

A Real-World Experience of Desidustat in Maintenance Hemodialysis Patients-A 1-Year Retrospective Database Analysis From a Single Center: Desidustat-A Real World Experience in Hemodialysis Patients From a Single Center. Desidustat在维持性血液透析患者中的真实世界经验-来自单一中心的1年回顾性数据库分析：Desidustat-来自单一中心的血液透析患者的真实世界经验。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-03-01 Epub Date: 2025-03-03 DOI: 10.1111/sdi.13249

Tarun Jeloka, Priyanka Sanwaria, Saurabh Khiste

{"title":"A Real-World Experience of Desidustat in Maintenance Hemodialysis Patients-A 1-Year Retrospective Database Analysis From a Single Center: Desidustat-A Real World Experience in Hemodialysis Patients From a Single Center.","authors":"Tarun Jeloka, Priyanka Sanwaria, Saurabh Khiste","doi":"10.1111/sdi.13249","DOIUrl":"10.1111/sdi.13249","url":null,"abstract":"Background: The long-term efficacy and safety of desidustat in real world are unknown. We conducted a retrospective real-world experience of desidustat in 100 consecutive patients on hemodialysis.Materials and methods: The first 100 consecutive stable patients on hemodialysis who were prescribed desidustat between May and December 2022, without history of infection, surgery, chronic hepatitis, or HIV infection, 1 month prior to initiation, were eligible for analysis from electronic records. Those who were lost to follow up, underwent transplantation, or discontinued medicine within 6 months were excluded. We looked at mean dose; efficacy at 1, 6, and 12 months; side effects; and adherence of desidustat over a period of 12 months.Results: Out of 100, 59 patients completed 1 year of the drug and were analyzed. There was statistically significant increase in hemoglobin from baseline to 1 month (9 ± 1.2 vs. 9.4 ± 1.3 g/dL, p = 0.01) and from baseline to 12 months (9 ± 1.2 vs. 9.9 ± 1.5 g/dL, p = 0.02). The percentage of patients who achieved target hemoglobin of 10-12 g/dL was 17% at baseline, which increased to 19.1% at 1 month, 43% at 6 months, and 38.9% at 12 months. Side effects were noted in 20% of patients, with edema being the most common (6%) and infections in 5% of cases. Nonadherence was observed in 15% patients.Conclusion: Desidustat is effective and safe in management of anemia in hemodialysis patients over a period of 1 year. It helps in achieving target hemoglobin in majority of patients within 6 months.","PeriodicalId":21675,"journal":{"name":"Seminars in Dialysis","volume":" ","pages":"139-145"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Use of Single Pass Albumin Dialysis and Hemoadsorption in Management of Life-Threatening Amlodipine Overdose. 单次白蛋白透析和血液吸附在治疗危及生命的氨氯地平过量中的应用。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-03-01 Epub Date: 2024-12-24 DOI: 10.1111/sdi.13236

Wun Fung Hui, Ann Wing Man Choi, Wing Lum Cheung, Kam Lun Hon, Shu Wing Ku

引用次数: 0

Mobile Applications for Hemodialysis: Evaluation Using the Mobile App Rating Scale (MARS). 血液透析的移动应用程序：使用移动应用程序评分量表（MARS）进行评估。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-03-01 Epub Date: 2025-02-06 DOI: 10.1111/sdi.13243

Erfan Esmaeeli, Mohadeseh Sadat Khorashadizadeh, Meysam Rahmani

{"title":"Mobile Applications for Hemodialysis: Evaluation Using the Mobile App Rating Scale (MARS).","authors":"Erfan Esmaeeli, Mohadeseh Sadat Khorashadizadeh, Meysam Rahmani","doi":"10.1111/sdi.13243","DOIUrl":"10.1111/sdi.13243","url":null,"abstract":"Introduction: Mobile applications (apps) and social media could be useful in improving the condition of patients on hemodialysis. Despite the rise of mobile health apps in hemodialysis management, no research has evaluated the quality of these apps with reliable tools. This study aimed to evaluate the quality of apps designed for the self-care of patients on hemodialysis.Materials and methods: A review of Google Play and App Store mobile platforms was carried out to evaluate the mobile apps used for hemodialysis. These apps were assessed using the mobile application rating scale (MARS), which includes criteria for overall quality, engagement, functionality, aesthetics, and information. Search keywords included \"Dialysis,\" \"Kidney Dialysis,\" \"Hemodialysis,\" \"Haemodialysis,\" and \"Peritoneal Dialysis.\" Eligibility criteria included being related to dialysis, being designed specifically for patients, being free, being available in English, and being developed for Android and iOS platforms. The included apps were independently evaluated and rated by two reviewers using MARS.Results: Initially, 177 apps were identified, and after the screening and review processes, six apps were selected for qualitative evaluation. The overall scores on MARS varied from 2.33 to 3.67. The \"KidneyPal: Kidney Disease Mgmt\" app received the highest scores in most MARS items. Moreover, the maximum app quality mean score belonged to \"KidneyPal: Kidney Disease Mgmt\" (4.26 out of 5).Conclusion: The findings showed a limited number of apps available for hemodialysis, the majority of which were of low quality. The reviewed apps performed well in functionality but obtained lower scores in terms of app subjective quality. Future studies should focus on developing and testing mobile apps using assessment tools, such as MARS, as well as evaluating their impact on health behaviors and outcomes.","PeriodicalId":21675,"journal":{"name":"Seminars in Dialysis","volume":" ","pages":"102-110"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Optimal Time of Percutaneous Pharmacomechanical Thrombolysis for the Treatment of Thrombosed Hemodialysis Arteriovenous Graft. 经皮药物力学溶栓治疗血栓性血液透析动静脉移植物的最佳时机。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-03-01 Epub Date: 2025-03-03 DOI: 10.1111/sdi.13251

Keerati Hongsakul, Surasee Srihasarn, Phurich Janjindamai, Surasit Akkakrisee, Kittipitch Bannangkoon, Sorracha Rookkapan, Ussanee Boonsrirat

{"title":"The Optimal Time of Percutaneous Pharmacomechanical Thrombolysis for the Treatment of Thrombosed Hemodialysis Arteriovenous Graft.","authors":"Keerati Hongsakul, Surasee Srihasarn, Phurich Janjindamai, Surasit Akkakrisee, Kittipitch Bannangkoon, Sorracha Rookkapan, Ussanee Boonsrirat","doi":"10.1111/sdi.13251","DOIUrl":"10.1111/sdi.13251","url":null,"abstract":"Background: The optimal time for the salvaging of thrombosed hemodialysis grafts is controversial. This study was aimed at determining the optimal time related to the outcome of percutaneous pharmacomechanical thrombolysis (PMT) for the treatment of thrombosed arteriovenous graft (AVG).Methods: This was a retrospective study of 191 hemodialysis patients who underwent PMT for thrombosed AVG from April 2014 to December 2021. Demographic data and details of the procedure were recorded. The procedural success rate related to the onset time of PMT was analyzed. The postinterventional circuit primary assisted patency rate was presented by the Kaplan-Meier curve.Results: A total of 191 hemodialysis patients, 101 females and 90 males, were enrolled. Their median age was 66 years (interquartile range of 58-75 years). The majority type of thrombosed AVG was brachiocephalic loop graft (60.2%). The procedural success rate of PMT that was performed ≤ 48 h was 86.2%. There was a statistically significant procedural success rate of PMT in the group with an onset of treatment ≤ 48 h compared to > 48 h (odds ratio = 2.77; 95% confidence interval = 1.06, 7.28; p = 0.037). The median postintervention circuit primary assisted patency in the group of treatment ≤ 48 and > 48 h was 7.3 and 3.9 months (p = 0.023), respectively.Conclusion: From this study, the optimal time of PMT for treatment of thrombosed AVG should be within 48 h after onset of thrombosis for enhancing procedural success and patency rates.","PeriodicalId":21675,"journal":{"name":"Seminars in Dialysis","volume":" ","pages":"132-138"},"PeriodicalIF":1.4,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two Cases of Acquired Reactive Perforating Collagenosis in Hemodialysis Patients. 血液透析患者获得性反应性穿孔性胶原沉积2例。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-02-10 DOI: 10.1111/sdi.13244

Min Xu, Fale Cao, Shumei Shi

引用次数: 0

Hardware in Dialysis Treatment: A Comprehensive Review. 透析治疗中的硬件：综合综述。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-01-01 Epub Date: 2025-02-12 DOI: 10.1111/sdi.13245

Bernard Canaud, Sydney Tang

引用次数: 0

Feedback control in hemodialysis. 血液透析中的反馈控制。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-01-01 Epub Date: 2023-11-23 DOI: 10.1111/sdi.13185

Ashveer Randhay, Mohamed Tarek Eldehni, Nicholas M Selby

引用次数: 0

Water and dialysis fluid purity for contemporary hemodialysis. 当代血液透析用水和透析液纯度。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-01-01 Epub Date: 2023-09-11 DOI: 10.1111/sdi.13174

Bernard Canaud, Rui Lucena, Richard Ward

{"title":"Water and dialysis fluid purity for contemporary hemodialysis.","authors":"Bernard Canaud, Rui Lucena, Richard Ward","doi":"10.1111/sdi.13174","DOIUrl":"10.1111/sdi.13174","url":null,"abstract":"Introduction: The purity of water and dialysis fluids is of utmost importance in ensuring the safe and effective administration of hemodialysis treatment to patients with chronic kidney disease. It is crucial to enforce compliance with international standards for dialysis water and fluids, as this is mandatory in reducing chemical hazards, mitigating the adverse effects of bioincompatibility resulting from contaminated water and ultimately enhancing long-term patient outcomes.Standards and risks: Within this comprehensive review, we highlight the presence of water contaminants and thoroughly assess the existing international standards for dialysis water and fluids, spanning from pure to ultrapure. Additionally, we delve into the fundamental components of water purification and present a comprehensive range of water treatment options, encompassing pre-treatment, primary treatment (reverse osmosis), and tertiary water treatment. Furthermore, we outline recommended monitoring and maintenance procedures, ensuring the consistent delivery of high-quality water and dialysis fluids at the point of care. WATER PURIFICATION AND MONITORING SUSTAINABILITY AND FUTURE CHALLENGES: Importantly, we raise concerns regarding the sustainability and conservation of water resources in hemodialysis treatment. It is imperative that these concerns be addressed in the future to avert the potential shortage of this essential resource.Conclusion: In conclusion, the contemporary landscape of hemodialysis conditions has engendered an urgent necessity for advanced water treatment systems and optimized delivery of dialysis fluids. This review serves as a comprehensive update on the latest technological advancements aimed at meeting these critical demands. Dialysis water and fluids must adhere to increasingly stringent purity constraints, encompassing both biochemical and microbiological perspectives.","PeriodicalId":21675,"journal":{"name":"Seminars in Dialysis","volume":" ","pages":"12-24"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10267821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pioneering Advances in Hemodialysis: A Review of Contemporary Machines. 血液透析的开创性进展：当代机器的回顾。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-01-01 Epub Date: 2025-02-13 DOI: 10.1111/sdi.13248

Vikram Mitra, Syed Zaidi, Sandip Mitra

引用次数: 0

The Revival of Sorbents in Chronic Dialysis Treatment. 吸附剂在慢性透析治疗中的复兴。

IF 1.4 4区医学

Seminars in Dialysis Pub Date : 2025-01-01 Epub Date: 2024-03-20 DOI: 10.1111/sdi.13203

Jeroen Peter Kooman

{"title":"The Revival of Sorbents in Chronic Dialysis Treatment.","authors":"Jeroen Peter Kooman","doi":"10.1111/sdi.13203","DOIUrl":"10.1111/sdi.13203","url":null,"abstract":"Interest in the use of sorbents in chronic dialysis treatment has undergone a revival in the last decades, for which two major factors are responsible. The first is the potential of sorbents as adjunct therapy for the removal of substances that are difficult to remove by conventional dialysis therapies. The second is their use in regeneration of dialysate, which is of pivotal importance in the design of portable or even wearable treatments, next to the potential for reducing water use during conventional dialysis treatment. Sorbent-enhanced dialysis with synthetic polymers was associated with a reduction in inflammatory parameters as compared to hemodialysis and even associated with improved survival in smaller studies, although this needs to be confirmed in large randomized trials. Incorporation of sorbents within a dialysis membrane (mixed matrix membrane) appears a promising way forward to reduce the complexity and costs of a dual therapy but needs to be tested in vivo. For regeneration of dialysate, at present, a combination of urease, zirconium-based sorbents, and activated charcoal is used. Next to sodium release by the sorbent in exchange for ammonium and the CO2 release by the hydrolysis of urea has been a bottleneck in the design of wearable devices, although short-term trials have been performed. Still, for widespread and flexible application of sorbent-assisted portable or wearable devices, a direct urea sorbent would be a major asset. In the near future, it will likely become apparent whether sorbent-assisted dialysis techniques are feasible for routine implementation in clinical practice.","PeriodicalId":21675,"journal":{"name":"Seminars in Dialysis","volume":" ","pages":"54-61"},"PeriodicalIF":1.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140176323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0